Navigation Links
Sectra and Philips Complete Modality Transaction
Date:9/1/2011

SHELTON, Connecticut, September 1, 2011 /PRNewswire/ --

Sectra (NASDAQ OMX Stockholm: SECT B) has completed a mammography-modality deal with Royal Philips Electronics (AEX: PHI, NYSE: PHG). Philips will pay EUR 57.5 million in a cash-on-cash and debt-free basis and take over the acquired modality operation today, September 1, 2011.

"The deal with Philips will give us the resources we need to continue our efforts and expand our business. In Medical Systems, we can concentrate on our core business and aim for a larger share of the market growth for medical imaging IT systems, which is growing rapidly," says Torbjörn Kronander, President of Sectra's medical systems operation.

     (Logo: http://www.newscom.com/cgi-bin/prnh/20110627/465018 )

The divested operation represented 14% of the Sectra Group's net sales for fiscal year 2010/2011 and has approximately 110 employees. The transaction comprises Sectra's mammography-modality operations worldwide, except for Australia and New Zealand where Sectra will continue to sell and service the unique MicroDose mammography modality under a separate distribution agreement with Philips.

The agreement includes an additional earn-out of EUR 12.5 million, which will fall due if the agreed terms and conditions are achieved over a period of five years. This transaction, excluding the possible earn-out, is estimated to generate a capital gain in terms of earnings of about SEK 300 million after tax for Sectra.

Focus ON medical IT

Sectra is one of the world's largest suppliers of medical imaging IT solutions. Sectra provides radiology, mammography, orthopeadic and rheumatology clinics with medical-imaging IT solutions and services that enhance the efficiency of medical care, contribute to raising the quality of care a
'/>"/>

SOURCE Sectra
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator
2. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
3. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
4. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
5. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
6. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
7. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
8. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association
11. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... Nov. 21, 2014  The element of surprise has ... i.e., they strike without warning. Until now, epidemiologists had ... a viral outbreak, resulting in suboptimal responses to both ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... been removed because virus gene structural changes have been ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 Author Matthew ... Walk to the Other Side” published as a ... Finalist in the “Fiction: Short Story” category of the ... Keen, President and CEO of USA Book News, said ... and independent publishers, including Simon & Schuster, Penguin, John ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... , MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM ... a life sciences product development company that identifies and ... various stages of development, today reported that Cytopia (ASX:CYT) ... CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The trial is ...
... , BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. ... as its President and CEO. , Abrams brings more than ... He is a co-inventor of the nuclear medicine imaging agent, ... plc where he was Manager, Biomedical Research Worldwide. In 1996, ...
... , , , , , , ... , , AUDIO: ... , Click here for more information. , ... , , , , ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 5Inimex Announces Appointment of New CEO 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... Researchers at Woods Hole Oceanographic Institution (WHOI) have developed ... represent the acoustic equivalent of the leap from black-and-white ... mean a major upgrade in their ability to count ... seas of turbulence. Lead authors Tim Stanton and ...
... limped off the pitch, thereby ending his chances of ... injuries and rehabilitation techniques were once again front and ... to one player,s Achilles tendon is a sign of ... of research. Now Paul Comfort and Earle Abramson,s pioneering ...
... reagents have been developed for C. Elegans micro RNA. ... Silence have created the first class of reagents ... used model organism. Wen-hong Li, from the University ... team of researchers including Dr. Genhua Zheng and Dr. ...
Cached Biology News:Now in broadband: Acoustic imaging of the ocean 2Now in broadband: Acoustic imaging of the ocean 3Now in broadband: Acoustic imaging of the ocean 4Now in broadband: Acoustic imaging of the ocean 5Sports rehabilitation and injury prevention 2
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Assay Diluent Trial Pack, 4 x 100 mL...
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the internall ... Reactivity: Mouse (positive controls: mouse brain ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
Rabbit anti-Junctophilin-4 (C-term)...
Biology Products: